SOLICITATION NOTICE
B -- DNA Methylation Services - Rorensic Genotyping of FHS samples
- Notice Date
- 8/31/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2011-339-DDC
- Archive Date
- 9/19/2011
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, for the Framingham Heart Study under the NHLBI, Division of Intramural Research (DIR) Center for Population Studies, intends to award a purchase order on a sole source basis for the purchase of DNA Methylation Services from Boston University School of Medicine. The reference number: NHLBI-CSB-(HL)-2011-339-DDC. Background: Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute; NHLBI) -- embarked on an ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. The objective of the Framingham Heart Study was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The Framingham Heart Study continues to make important scientific contributions by enhancing its research capabilities and capitalizing on its inherent resources. New diagnostic technologies, such as echocardiography (an ultrasound examination of the heart), carotid-artery ultrasound, bone densitometry (for monitoring osteoporosis), and computerized tomography of the coronary arteries, are evaluated and integrated into ongoing protocols. While pursuing the study's established research goals, the NHLBI and the Framingham investigators are expanding their research into other areas such as the role of genetic factors in CVD. Framingham investigators also collaborate with leading researchers from around the country and throughout the world on projects in stroke and dementia, osteoporosis and arthritis, nutrition, diabetes, eye diseases, hearing disorders, lung diseases, and genetic patterns of common diseases. Purpose: This project seeks to characterize DNA Methylation in promoter regions of genes. Studies of DNA Methylation (one element of what is now termed "epigenetics") reveal that DNA Methylation is closely linked to gene expression and it is also a prominent contributor in a variety of complex disorders. The Government proposes to investigate DNA Methylation; with this DNA Methylation data set, the Government will have the ability to study gene regulation from different perspectives. The process of DNA Methylation requires DNA isolation of bulk buffy coat samples, there shall produce several hundred micrograms o D NA of which only a small amount will be used in the assay. The remaining DNA needs to be genotyped prior to re-entry into the Framingham DNA archives. Period of Performance: September 15th 2011 through June 30th 2012. Contractor Requirements: A. Contractor (FHS Genetic Lab) shall provide services to genotype and aliquot DNA from the Framingham Heart Study buffy coat samples. B. The Contractor shall utilize the Ampflstr Genotyping Kit C. Remaining isolated DNA will be aliquoted into appropriate size aliquots and returned to FHS Genetics lab for storage and consumption as determined by the FHS Genetics Committee. Government Responsibilities: NHLBI will provide to the Contractor plates with standard concentrations of DNA and identifiers for each plate. In addition, NHLBI will provide a list of identifiers for each DNA sample within each plate. Reporting Requirements and Deliverables: Return of results by the Contractor will be accompanied by summary quality control measures for each sample. Genotyping data will be returned to FHS within 20-30 weeks of receipt of the DNA samples Program Management and Control Requirements: No special management or control systems are required under this contract. Overall the contract will be managed though the Principle Investigator; Dan Levy The sole source determination is based on the fact the National Institute of Health (NIH) is the nation's medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people's health and save lives. The existing knowledge of DNA Methylation in humans, especially related to CVD risk, is in its very preliminary stages. The availability of new, high throughput technology and the extensive resources of the FHS and the SABRe CVD Initiative provide a timely, invaluable platform upon which Epigenetic research can build. Therefore, the Government needs to purchase a Forensic Genotyping of 2270 DNA samples from Offspring Exam 8, from the Boston University genetics core laboratory part of FHS. 1. The DNA shall be entered into FHS archives and stored at Boston University laboratory, and all non-renewable resources samples returning to the FHS laboratory must genotyped with this procedure before being entered into the collection. 2. The DNA that will be obtained from the buffy coat source will generate>300ug of total DNA of which the Government will only utilize 3ug. The remaining DNA will need to be carefully aliquoted, labeled and stored by the FHS genetics core laboratory to ensure these samples remain in their most pristine state possible so these can be utilized to fulfill future requests of the FHS DNA committee. Since the buffy coast is non-renewable resource, the utmost care must be used to maximize the recovery and properly archive these materials for later use. Due to these two conditions, it is essential that the DNA isolation work requested be conducted at Boston University genetics core laboratory linked with the FHS to maintain the best possible chain of custody and sample state for these non-renewable resources from Framingham collection. The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Framingham Heart Study, 73 Mt. Watye Avenue Perini Building, Framingham MA 01702. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology with size standard of 500 employees; the small business set-aside does not apply for this requirement. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-53 (August 4th 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by September 4th 2011, 7:30 am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-339-DDC, may be submitted to the COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-339-DDC/listing.html)
- Place of Performance
- Address: NHLBI/NIH, Framingham Heart Study, 73, Mt Watye Avenue Perini Building, Framingham, Massachusetts, 01702, United States
- Zip Code: 01702
- Zip Code: 01702
- Record
- SN02558116-W 20110902/110901000727-8c58e6c284d9e2865ab2d4d5a08af3d4 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |